about
Role of the Receptor for the Globular Domain of C1q Protein in the Pathogenesis of Hepatitis C Virus-Related Cryoglobulin Vascular DamageRole of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewAndrogen receptor signaling pathways as a target for breast cancer treatmentCell-free DNA as a diagnostic marker for cancer: current insightsBarrett's esophagus and esophageal cancer: an overview.T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia.Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study.Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.H. pylori infection and gastric cancer: state of the art (review).Metabolic syndrome as a peculiar target for management of prostate cancer patients.Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.Precancerous colorectal lesions (Review).Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.The emerging role of anti-angiogenic therapy in ovarian cancer (review).Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.The potential use of urine cell free DNA as a marker for cancer.Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus.Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis.Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia.Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
P50
Q27490515-946B49A0-C232-4A1C-8C2E-52A507FE6461Q28069963-C0CB8AFA-1A39-4AF2-94D1-D91BC8789142Q28071797-FA0D9230-F141-4C46-91CE-49B0C9C01428Q28074556-9CEBB2D4-00F7-4079-8FA7-0568F641607EQ34276384-8C3F3ED5-8C87-49AF-8B71-77CEA599EB10Q34662450-F1086A80-404E-4F5D-AB17-EEF44A14CACAQ35603660-2248D36E-C0FD-4337-96FD-E8D37F0474D2Q35863880-3036DD01-9877-413F-ADD5-655756152999Q36008985-2304CA96-E2A1-4D7A-A1F4-5E164962F6F0Q36081801-A642EA86-D8F9-4EBF-86A3-75493A081DDDQ37290050-73F6BCA0-0C0C-465D-B819-B5AFCD8ACFF9Q37335554-82E3D842-1E04-467A-8294-C759BAFB9DEAQ37688103-33FC61F7-FF99-47D4-9287-3A1D37F7FD11Q38054930-8B6A34E0-718C-4E5D-B454-06F8C2FC306BQ38061048-D50825B9-FB37-467D-A4FA-6A5CFFD088F5Q38108927-F542BA10-132B-4E32-ADCC-9EBC2B060BE5Q38117717-B90709E0-3603-438E-A07E-485656A0A1A2Q38125394-E7248D69-6B39-49C9-ABFF-3377AB07E994Q38135186-75B94FC0-559B-49A2-804A-6ABD6AC34868Q38195731-987DFF9C-89F6-4ACA-8501-63A2456F08FFQ38222242-F009EB10-18F5-47C1-8698-AA13F9A51723Q38620751-DD9C8FB2-BAE8-47D0-9648-D0864FDA484EQ38804089-3BBC7790-14E3-4D90-8E0E-B6BE1BE4E494Q38827364-C52AD370-433E-4255-90A7-818F596E719EQ38833996-B2AB6651-23CE-44FF-9412-5B668D0F49EFQ38906250-D3B709D4-FCFE-49F9-85C9-DC14247FAADFQ38956775-17C0D5EE-5C9B-495B-A2DA-A02519544081Q38994581-DE6303E3-B557-4831-B1EE-7CF69C74F95BQ39883637-22229049-5FF7-44DB-85AB-4A24BC1C765DQ40374954-1CAB7328-1FE5-408B-984F-F843F6798850Q40527144-4C530F95-05E6-4C39-BC32-DB9A4DA8A95AQ40830449-2013315C-6B07-4320-B7D1-EE5083646CE3Q41161118-98895355-3BAE-4834-9623-FC1C8BFF9460Q41732768-DCC0EF12-6E00-483F-84C4-B05D72C1EF90Q41746316-FD33BC95-C887-4549-A532-F676AB402BB5Q42251872-87CBD43B-0944-44F9-B248-A311E074FCEDQ44108643-9FC52EFF-1007-462F-92AC-3A3A3257CE0FQ44453209-34908CFD-AE6D-452E-92E7-D5D294777F7CQ45354097-3EA78D92-DE81-448A-ACF2-46D8D2E5D207Q45377393-8695B7D4-364E-413C-BD51-44874268DD8A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vincenza Conteduca
@ast
Vincenza Conteduca
@en
Vincenza Conteduca
@es
Vincenza Conteduca
@nl
type
label
Vincenza Conteduca
@ast
Vincenza Conteduca
@en
Vincenza Conteduca
@es
Vincenza Conteduca
@nl
prefLabel
Vincenza Conteduca
@ast
Vincenza Conteduca
@en
Vincenza Conteduca
@es
Vincenza Conteduca
@nl
P106
P1153
25026993100
P31
P496
0000-0002-6921-714X